You are developing best in class product(s) or platform in healthcare and nutrition with a top quality team and entrepreneurial drive with a clearly defined pathway to value inflection points.
You are ready to achieve as much as you dare to strive.
We help you structure and expand your entrepreneurial project, operating as a genuine business partner. Our team is ready to share decades of experience in product development, manufacturing, regulatory affairs, intellectual property, as well as human resources management, thanks to our business and industrial network.
We believe the 21st century will be biology-driven, where the promise of precision medicine and a biology-led industrial revolution hinge on the ability to reduce the complex interconnections of large, multi-omic data sets into useful biological information, services and products. We believe that this will ultimately lead to a sizeable market opportunity, better and cost-effective healthcare, while also addressing large social challenges such as a sustainable food supply chain.
OMX Europe Venture Fund (2020)
Omics [ō-miks]: Refers to a field of study in biology ending in -omics (such as genomics, proteomics, metabolomics, microbiomics, etc.) in a cell, organ, or organism.
OMX Europe Venture Fund is a life science venture fund managed by Mérieux Equity Partners with the co-sponsorship of Korys and Mérieux Développement. The Fund, through its direct link with Korys, brings together decades of expertise of investing and supporting entrepreneurship in the life science and nutrition sectors. The Fund’s strategy is to invest in highly innovative companies and best-in-class platforms at pre-commercial or commercial stage in Western Europe and North America. The fund also operates in close collaboration with OMX Ventures – a US-based fund – providing privileged access to great science and strong relationships with entrepreneurs in North America.
Mérieux Participations 2 (2014)
Mérieux Participations 1 (2009)
Date: April 2021 / Source: Mérieux Equity Partners
Disclaimer: This page is dedicated to entrepreneurs. The information on this page should not be construed as an invitation to invest.
Our business partners include OMX Ventures in the US as well as Senior Advisors, Korys, M2Care and Sofimac Innovation in Europe.
OMX Ventures is a US-based committed capital fund focused on investing in bio tools and therapeutics startups primarily at the intersection of data/engineering and biology. They typically make their first investment in the Seed or Series A rounds, then reserve for every subsequent round. They aim to support the CEOs of their portfolio companies in go-to-market, product marketing, fundraising, hiring, intellectual property, product development, organizational structure, sales, manufacturing, and software development. They partner on every deal with other VCs.
Korys is the family office of the Belgium-based Colruyt family. Today, it has €5 billion of assets under management. Besides holding a significant participation in the Colruyt Group - a leading retail company in Belgium and France - it actively manages participations in privately held companies, private equity funds and quoted financial instruments. Across its activities, Korys’ investment decisions are taken with a long-term perspective and on the basis of strict economic (Profit), social (People) and ecological (Planet) criteria in order to create sustainable value in three major ecosystems: Life Sciences, Energy Transition and Conscious Consumer. To do this, Korys can count on a motivated team of 30 professionals based in Belgium and Luxembourg.
M2Care is a Venture studio launched in 2019 and operated by Waoup and located in France that offers a differentiated model at the crossroads of innovation, investment and technology - dedicated to build and/or accelerate disruptive startups and ventures. M2Care is working with key actors of the innovation sector: start-ups, corporates, VCs and TTOs with the aim of derisking all new and existing businesses. They bring an international experienced ecosystem to manage all business dimensions : 60+ experts & partners, specialized in all stages of development in MedTech / Biotech / Nutrition projects.
Pertinence Invest 2 (“PI2”) is a Seed Fund launched in 2020 by Sofimac Innovation, in partnership with French leading engineering schools and universities, focusing on industry 4.0, new energies, new materials, digitalization and breakthrough platforms serving the Health & Nutrition sectors. This program federates an entire eco-system including some of the leading industrial companies in France (bioMérieux, Michelin, Seb, etc.) and it supports start-ups that have emerged directly from the research labs of its academic partners or are directly linked to them.
Mérieux Equity Partners is an advisor to PI2 for investments in the health and nutrition sectors. The Fund's strategy is to invest in highly innovative companies and best-in-class platforms at early stage of development with ticket sizes ranging from €0.3M to €3M.